🇺🇸 FDA
Pipeline program

EXS73565

EXS73565-001

Phase 1 small_molecule active

Quick answer

EXS73565 for Relapsed or Refractory B-cell Malignancies is a Phase 1 program (small_molecule) at RECURSION PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
RECURSION PHARMACEUTICALS, INC.
Indication
Relapsed or Refractory B-cell Malignancies
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials